What long-term side effects have been reported with Cosentyx (secukinumab)?
Cosentyx (secukinumab) is a long-term treatment for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The long-term risks people ask about are the same types of safety issues seen across treatment years: ongoing infection risk, certain immune-related reactions, and possible effects on lab tests. Serious adverse events reported in clinical use include infections; immune-related conditions such as inflammatory bowel disease; and hypersensitivity reactions.[1][2]
The prescribing information emphasizes that infections can occur during treatment, including serious infections. Because therapy is continuous for many patients, the concern is not only whether an infection happens, but whether risk persists with ongoing dosing.[1][2]
How does infection risk change with long-term use?
Long-term immunomodulation can increase susceptibility to infections. Cosentyx use has been associated with infections (including serious infections) in patients treated with secukinumab, and the label advises monitoring and prompt evaluation of infection symptoms during treatment.[1][2]
If someone develops a serious infection, treatment typically needs to be reconsidered until the infection is controlled, and that decision is usually individualized with the prescribing clinician.[1][2]
Is inflammatory bowel disease (IBD) a long-term concern?
Yes. Cosentyx has been linked to worsening or new onset inflammatory bowel disease in some patients, including cases of Crohn’s disease and ulcerative colitis.[1][2]
Patients with existing IBD are often counseled to discuss risk and monitoring. If new gastrointestinal symptoms occur during therapy, clinicians usually evaluate for IBD and other causes.[1][2]
What immune or allergic reactions can occur over years?
Cosentyx can cause hypersensitivity reactions, including serious allergic-type reactions. These can occur at any time during treatment, so the “long-term” issue is that risk does not end after the first months.[1][2]
What long-term lab or safety monitoring is recommended?
The Cosentyx label focuses on safety monitoring that reflects its immunologic effects and the infections/immune reactions discussed above. In practice, clinicians may check relevant labs as appropriate for the individual patient and other therapies used, particularly when symptoms suggest infection or immune complications.[1][2]
Are there long-term cancer risks or major organ toxicity concerns?
Cosentyx does not carry the same class-specific warnings as some older immunosuppressants, but the possibility of rare long-term outcomes is part of why ongoing pharmacovigilance continues. The most clearly emphasized long-term safety themes in the label are infections and immune-related conditions like IBD, rather than specific organ-toxicity signals.[1][2]
What should patients watch for during long-term treatment?
Common “watch-for” themes tied to long-term risk are symptoms of infection (fever, worsening cough, painful urination, etc.) and symptoms that could suggest IBD (persistent abdominal pain, diarrhea, blood or mucus in stool). Hypersensitivity symptoms (rash, swelling, trouble breathing) also warrant urgent evaluation.[1][2]
How do risks compare across different conditions and doses?
Cosentyx is used at different dosing schedules depending on the condition (and sometimes the patient). While the label reports safety across indications, the real-world risk pattern can vary by baseline health, prior biologic exposure, comorbidities (especially IBD and infection risk), and whether other immunosuppressive drugs are used alongside it.[1][2]
Where to find the exact “long-term” adverse reaction language?
The most accurate source for long-term side effects is the prescribing information’s adverse reactions section and the warnings/precautions sections (infection; inflammatory bowel disease; hypersensitivity). Those sections are where the label summarizes serious risks and ongoing concerns during treatment.[1][2]
---
Sources
[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/2024/125514s188lbl.pdf
[2] https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-informationen.pdf